Pacific Biosciences achieves second development milestone in clinical diagnostics agreement with Roche


Pacific Biosciences of California, Inc., provider of the PacBio(R) RS II Sequencing System, announced that it has achieved a second development milestone under its development, commercialization and license agreement with F. Hoffman-La Roche Ltd (Roche), earning an additional $10 million.

The development, commercialization and license agreement with Roche covers diagnostic products for clinical use, including sequencing systems and consumables based on Pacific Biosciences' Single Molecule, Real-Time (SMRT(R)) technology. Under the agreement, Roche has the exclusive right to commercialize and sell the developed diagnostic products for clinical use, subject to certain terms and conditions.

Pacific Biosciences received from Roche a non-refundable up-front payment of $35 million in September 2013, and was eligible to receive up to an additional $40 million based upon the achievement of development milestones. Pacific Biosciences has now earned $20 million of the $40 million potential milestone payments pursuant to the agreement.

"We are on track to deliver a system to Roche by the second half of next year, consistent with our original target," said Michael Hunkapiller, President and CEO of Pacific Biosciences. "I have been very pleased to see the productive spirit of collaboration under which our companies have been working for the last 18 months, and I'm confident that we will continue our record of milestone achievement for the duration of the development project."

Dan Zabrowski, Head of Sequencing and Tissue Diagnostics at Roche commented: "We are very pleased with the progress on this collaboration, and look forward to transitioning from product development to product sales in the future. Our goal has been to accelerate the integration of DNA sequencing into routine diagnostics, and we believe we are well on our way to achieving this with PacBio."

The proceeds from the development milestone will be recognized as contractual revenue in the Pacific Biosciences financial statements for the quarter ending June 30, 2015.



May 12, 2015


Topic Area: Press Release


Recent Posts

Harris Health to Build New Freestanding Cancer Center

The center is planned to open in 2029, following the opening of the new O'Quinn Hospital along the North Loop at Lockwood.


Inland Empire Health Plan Opens Expanded San Bernardino Community Wellness Center

The new 33,000-square-foot center is nearly three times the size of the original location off Second Street.


Rethinking Parking Lot Design at Irvine Heritage Medical Plaza

A new solar installation shows how healthcare facilities can improve parking amenities while boosting energy savings


Repurposing Healthcare Spaces: 5 Critical Questions

Done well, converting existing spaces can trim upfront project costs by up to 40 percent, compared with ground-up construction


Disinfectant Contact Time: The Case for Biofilm Disruption

Contact time, while essential for compliance, does not reliably predict microbial reduction on actual healthcare surfaces.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.